García‐Carbonero, R., van Cutsem, E., Rivera, F., Jassem, J., Gore, I., Tebbutt, N., . . . Hurwitz, H. (2017). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. The oncologist (Dayton, Ohio), 22(4), 375-e30. https://doi.org/10.1634/theoncologist.2016-0133
Citace podle Chicago (17th ed.)García‐Carbonero, Rocío, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio) 22, no. 4 (2017): 375-e30. https://doi.org/10.1634/theoncologist.2016-0133.
Citace podle MLA (9th ed.)García‐Carbonero, Rocío, et al. "Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer." The Oncologist (Dayton, Ohio), vol. 22, no. 4, 2017, pp. 375-e30, https://doi.org/10.1634/theoncologist.2016-0133.